A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Phase 3
40
about 4.1 years
9–17
12 sites in AZ, CA, DC +6
About this study
Researchers are testing a treatment called bimekizumab in children and adolescents with moderate to severe hidradenitis suppurativa. The trial will examine how well this medication works (pharmacokinetics) and its safety.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Bimekizumab
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
bimekizumab
Secondary: Exposure-adjusted incidence rate of Serious TEAEs during the Initial Treatment Period, Exposure-adjusted incidence rate of TEAEs leading to withdrawal during the Initial Treatment Period, Exposure-adjusted incidence rate of Treatment- Emergent Adverse Events (TEAEs) during the Initial Treatment Period, Mean Change from Baseline in Biochemistry Laboratory Analyses (alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase) at Weeks 4,12, and 16, Mean Change from Baseline in Biochemistry Laboratory Analyses (glucose, potassium, sodium, calcium) at Weeks 4,12, and 16, Mean Change from Baseline in Biochemistry Laboratory Analyses (total bilirubin and direct bilirubin, total protein, blood urea nitrogen, and creatinine) at Weeks 4,12, and 16, Mean Change from Baseline in Hematology Laboratory Analyses (erythrocytes), Mean Change from Baseline in Hematology Laboratory Analyses (hematocrit) at Weeks 4,12, and 16